Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001081117 | SCV000815118 | likely benign | Tuberous sclerosis 2 | 2024-10-21 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000687545 | SCV001146287 | uncertain significance | not provided | 2019-06-04 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001081117 | SCV002040219 | likely benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002334263 | SCV002639335 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-08-22 | criteria provided, single submitter | clinical testing | The p.R1580W variant (also known as c.4738C>T), located in coding exon 36 of the TSC2 gene, results from a C to T substitution at nucleotide position 4738. The arginine at codon 1580 is replaced by tryptophan, an amino acid with dissimilar properties. This amino acid position is poorly conserved in available vertebrate species. One functional study reported that this variant behaved similarly to wild-type as assessed by GAP activity levels (Hansmann P. et al. Structure. 2020 08;28(8):933-942). In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Baylor Genetics | RCV003459674 | SCV004205103 | uncertain significance | Isolated focal cortical dysplasia type II | 2024-02-22 | criteria provided, single submitter | clinical testing |